Oligodendroglioma Market Expected to Rise | Companies – EpicentRx, Pfizer, Oblato, Istari Oncology, Bayer, Chimerix, Pfizer, Abbott, Expected to Drive Market

Oligodendroglioma Market
DelveInsight’s “Oligodendroglioma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Oligodendroglioma, historical and forecasted epidemiology as well as the Oligodendroglioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Oligodendroglioma market growth is driven by factors like increase in the prevalence of Oligodendroglioma, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Oligodendroglioma market report also offers comprehensive insights into the Oligodendroglioma market size, share, Oligodendroglioma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Oligodendroglioma market size growth forward. 

Some of the key highlights from the Oligodendroglioma Market Insights Report:

Several key pharmaceutical companies, including EpicentRx, Pfizer, Oblato, Istari Oncology, Bayer, Chimerix, Pfizer, Abbott, and others, are developing novel products to improve the Oligodendroglioma treatment outlook. 
The total Oligodendroglioma market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
As per DelveInsight analysis, the Oligodendroglioma market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Oligodendroglioma Market Landscape

Oligodendroglioma Overview 

Oligodendroglioma (OG) is a type of diffusely infiltrating glioma and constitutes approximately 5% of primary intracranial tumors. Oligodendroglial tumors can be divided into two groups based on the classification of the world health organization (WHO): grade II oligodendroglioma and grade III (anaplastic) oligodendroglioma. Most commonly occurring between 25 and 45 years of age, grade III oligodendrogliomas tend to present 10 years later than grade II tumors and can rarely develop in younger and older populations. Oligodendroglioma is genetically defined as a tumor confirmed to harbor either an IDH1 or IDH2 mutation along with co-deletion of chromosome arms 1p and 19q.

OGs are found predominantly in the cerebral hemisphere white matter (80 to 90% supratentorial), most commonly in the frontal lobes, but temporal and parietal lobe involvement is not uncommon. Treatment of OG is multifactorial, consisting of surgical, chemotherapy, and radiation therapy treatment methods.

Surgical treatments are approached on a case-by-case basis. Radiation oncology with radiotherapy (RT) also plays an important role in the treatment of OG, most often after surgical resection. Standard focal or limited field hyperfractionated RT is typically employed. The field consists of the resection bed, area of residual enhancement on T1 post-contrast imaging, and a margin of up to 3 cm, including the adjacent T2/FLAIR hyperintensity that may represent infiltrating disease.

Do you know the treatment paradigms for different countries? Download our Oligodendroglioma Market Sample Report

Oligodendroglioma Epidemiology Segmentation 

DelveInsight’s Oligodendroglioma market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Oligodendroglioma historical patient pools and forecasted Oligodendroglioma patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Oligodendroglioma Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

Oligodendroglioma Prevalence 
Age-Specific Oligodendroglioma Prevalence 
Gender-Specific Oligodendroglioma Prevalence 
Diagnosed and Treatable Cases of Oligodendroglioma

Visit for more @ Oligodendroglioma Epidemiological Insights

Oligodendroglioma Treatment Market 

The Oligodendroglioma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Oligodendroglioma market trends by analyzing the impact of current Oligodendroglioma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Oligodendroglioma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Oligodendroglioma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Oligodendroglioma market in 7MM is expected to witness a major change in the study period 2019-2032.

Oligodendroglioma Emerging Drugs

ONC201: Chimerix

ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist in late-stage clinical development for recurrent gliomas that harbor the H3 K27M mutation. Recurrent glioma is a form of brain cancer with a particularly poor prognosis having a median overall survival of approximately eight months. Recurrent pediatric patients, with cancer that carries the H3 K27M mutation, have an even worse prognosis with median overall survival of approximately four months. Compelling responses at this stage of disease are rare and lack durability. Patients with this mutation are considered grade IV by the World Health Organization, regardless of underlying histology or age.

RRx-001: EpicentRx

RRx-001 is a lead small molecule, immunotherapy targeting the CD47 – SIRPα axis and has been evaluated in multiple clinical studies. The genesis for the PIRATE trial was based on several preceding clinical trials which have established potential evidence that RRx-001 increases chemotherapy delivery and uptake in tumors. A Phase 1 clinical trial called G-FORCE (NCT02871843) and a Phase 1/2 clinical trial called BRAINSTORM (NCT02215512) demonstrated the safety of RRx-001 as well as potential evidence of clinical benefit in adult patients with glioblastoma or GBM and with brain metastases, respectively.

Oligodendroglioma Key Companies

Istari Oncology

For more information, visit Oligodendroglioma Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Oligodendroglioma Market Report:

11 Years Forecast
7MM Coverage 
Descriptive overview of Oligodendroglioma, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Oligodendroglioma epidemiology in the 7MM
Oligodendroglioma marketed and emerging therapies 
Oligodendroglioma companies
Oligodendroglioma market drivers and barriers 

Key Questions Answered in the Oligodendroglioma Market Report 2032:

What was the Oligodendroglioma market share distribution in 2019, and how would it appear in 2032?
What is the total Oligodendroglioma market size and the market size by therapy across the 7MM for the study period (2019-32)?
What are the important findings from 7MM, and which country will have the greatest Oligodendroglioma market size from 2019-32?
During the study period (2019-2032), at what CAGR is the Oligodendroglioma market projected to expand at 7MM?

Table of Contents:

1 Oligodendroglioma Market Key Comprehensive Insights 

2 Oligodendroglioma Market Report Introduction

3 Competitive Intelligence Analysis for Oligodendroglioma

4 Oligodendroglioma Market Analysis Overview at a Glance

5 Executive Summary of Oligodendroglioma

6 Oligodendroglioma Epidemiology and Market Methodology

7 Oligodendroglioma Epidemiology and Patient Population

8 Oligodendroglioma Patient Journey

9 Oligodendroglioma Treatment Algorithm, Oligodendroglioma Current Treatment, and Medical Practices

10 Key Endpoints in Oligodendroglioma Clinical Trials

11 Oligodendroglioma Marketed Therapies 

12 Oligodendroglioma Emerging Therapies

13 Oligodendroglioma: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Oligodendroglioma

16 Oligodendroglioma Market Key Opinion Leaders Reviews

18 Oligodendroglioma Market Drivers

19 Oligodendroglioma Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Oligodendroglioma Epidemiology 2032

DelveInsight’s “Oligodendroglioma – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Oligodendroglioma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Oligodendroglioma Pipeline 2023

“Oligodendroglioma Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Oligodendroglioma market. A detailed picture of the Oligodendroglioma pipeline landscape is provided, which includes the disease overview and Oligodendroglioma treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: